Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tracheobronchopathia osteochondroplastica: clinical, bronchoscopic, and comorbid features in a case series.
Dumazet A, Launois C, Lebargy F, Kessler R, Vallerand H, Schmitt P, Hermant C, Dury S, Dewolf M, Dutilh J, Abouda M, Ferreira M, Atallah I, Lachkar S, Charriot J, Jouneau S, Uzunhan Y, Chouabe S, Coiffard B, Dutau H, Hagenburg J, Briault A, Dormoy V, Lirsac M, Vergnon JM, Deslee G, Perotin JM. Dumazet A, et al. Among authors: ferreira m. BMC Pulm Med. 2022 Nov 17;22(1):423. doi: 10.1186/s12890-022-02225-2. BMC Pulm Med. 2022. PMID: 36397041 Free PMC article.
[Osteochondroplastic tracheobronchopathy: About three cases].
Ferreira M, Morel H, Dixmier A, Arbion F, Marchand-Adam S. Ferreira M, et al. Rev Mal Respir. 2018 Sep;35(7):738-744. doi: 10.1016/j.rmr.2017.10.668. Epub 2018 Jun 23. Rev Mal Respir. 2018. PMID: 29945809 French.
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.
Ferreira M, Bejan-Angoulvant T, Marchand-Adam S, Mousset E, Mureau E, Jouneau S, Nunes H, Montani D, Chenivesse C, Cadranel J, Bonniaud P, Crestani B, Cottin V, Caille A; OrphaLung.. Ferreira M, et al. Respir Med Res. 2024 Nov 28;87:101144. doi: 10.1016/j.resmer.2024.101144. Online ahead of print. Respir Med Res. 2024. PMID: 39693827
Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study.
Ferreira M, Borie R, Crestani B, Rigaud P, Wemeau L, Israel-Biet D, Leroy S, Quétant S, Plantier L, Dalphin JC, Cottin V, Marchand-Adam S; of the OrphaLung network. Ferreira M, et al. Respir Med. 2020 Oct;172:106146. doi: 10.1016/j.rmed.2020.106146. Epub 2020 Sep 9. Respir Med. 2020. PMID: 32971360 Free article.
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, Girard N, Moro-Sibilot D, Cadranel J, Zalcman G, Ricordel C, Wislez M, Munck C, Poulet C, Gauvain C, Descarpentries C, Wasielewski E, Cortot AB, Baldacci S. Dehem A, et al. Among authors: ferreira m. Lung Cancer. 2023 Dec;186:107393. doi: 10.1016/j.lungcan.2023.107393. Epub 2023 Oct 9. Lung Cancer. 2023. PMID: 37839252 Free article.
Editorial: Impact of immunotherapy in lung cancer.
Ferreira M, Reckamp KL. Ferreira M, et al. Front Oncol. 2022 Nov 11;12:1083524. doi: 10.3389/fonc.2022.1083524. eCollection 2022. Front Oncol. 2022. PMID: 36439462 Free PMC article. No abstract available.
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB. Ferreira M, et al. Lung Cancer. 2024 Oct;196:107934. doi: 10.1016/j.lungcan.2024.107934. Epub 2024 Aug 24. Lung Cancer. 2024. PMID: 39277916 Clinical Trial.
6,133 results